Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole versus risperidone for obsessive-compulsive symptoms in bipolar disorder
IRCT20170716035117N1Phase 3Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obsessive compulsive disorder (OCD) and bipolar disorder (BD) comparing Aripiprazole arm with Risperidone arm (2 arms). Primary endpoints: Change in Y-BOCS score in the aripiprazole group and Change in Y-BOCS score in the risperidone group. Started Jul 2017; status: completed.
02
Drugs
aripiprazolerisperidone
03
Conditions
obsessive compulsive disorder (OCD)bipolar disorder (BD)
Beyond the preview
Go deeper on IRCT20170716035117N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170716035117N1.